Such NSCLC patients, who typically are non-smokers with adenocarcinomas, have been treated with crizotinib in first line (for ALK-positive cancers only) and, once the tumors become crizotinib-resistant and relapse, with other TKI inhibitors such as ceritinib35,36. Here, ALK is linked to adenocarcinoma.